CRWV fell another 7% this week to $81.85, extending the pullback that was already in motion when the previous note published — and this time, the most telling data point isn't the options market. It's the CEO's own activity in the stock.
CEO Michael Intrator filed sales totalling roughly $27 million on August 25, disposing of around 302,000 shares at prices in the high $80s. All transactions were executed under a pre-arranged 10b5-1 plan, which reduces the signalling value of any single trade — planned sales are compensation mechanics, not necessarily conviction calls. Even so, the 90-day insider net across all insiders is negative to the tune of $56 million, a figure that is hard to ignore as a backdrop when the stock is already giving ground. The GC also trimmed a small position the following day, again under a 10b5-1 plan. No open-market purchases appear in the recent record.
The positioning picture has shifted slightly since last week. The put/call ratio is still elevated at 0.82, about 1.6 standard deviations above the 20-day mean of 0.74 — less extreme than the spike to 0.87 and a z-score above 3.0 that flagged in the prior note, but still meaningfully above neutral. Options traders have not fully unwound their defensive posture. Meanwhile, short interest has nudged up 1.8% on the week to 14.6% of the free float — roughly 56 million shares — reversing a brief dip but remaining well below the late-July peak of around 90 million shares. Borrow availability has actually loosened, now running at 275%, up from the prior week and well above the 52-week tightest reading near 97%. Cost to borrow is 0.50%, up 20% week-on-week from a low base but still firmly in "easy borrow" territory. The lending market is not flashing any squeeze signal.
The Street continues to lean constructive, though the split is wide. Truist lifted its target to $165 on August 24, and Citi had already moved to $159 after the August 11 earnings beat. JPMorgan sits at $120 with a Neutral, Goldman at $139 also Neutral — and Bernstein carries an Underperform with a $74 target, the only bear below current trading levels. The consensus mean target is around $140, implying roughly 70% upside from where the stock trades today. That gap is as much a reflection of how far the stock has pulled back from post-earnings highs as it is of analyst conviction. EPS momentum ranks in the 87th percentile on a 90-day basis, and the ORTEX short score has drifted in a narrow band around 59-60 for the past two weeks — elevated, but not climbing.
The institutional register adds texture. BlackRock added over 14 million shares in the period to July 31, and Vanguard entities collectively added roughly 8 million shares around the same time. On the other side, co-founders Brian Venturo and Brannin McBee have both trimmed under their own plans. NVIDIA's disclosed stake, last filed in January, sits at 11.5% — a notable strategic anchor in the register. No 13D activist filings are on record; all major holders have filed passive 13G schedules, and the standard caveat applies: stakes are as-last-disclosed around the 5% threshold, and holders dropping below that level are not required to file again.
CRWV's most recent earnings print on August 11 produced a 22% next-day move — the kind of reaction that keeps the stock alive for momentum buyers even through difficult stretches. The next event is not until November 11, so the near-term catalyst calendar is thin. The stock's correlated peers had a rough week too: APLD fell 16%, WYFI dropped 14%, and SHAZ lost nearly 14% — suggesting broader sector pressure rather than anything specific to CoreWeave. The key variables to monitor over the coming weeks are whether the $104 billion backlog translates into updated revenue guidance ahead of schedule, and whether the CEO's ongoing 10b5-1 sales programme continues at pace or slows as the stock retreats further from his selling prices.
See the live data behind this article on ORTEX.
Open CRWV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
